Neoantigens are unique molecules produced by mutated genes in cancer cells or infected cells that are not present in normal cells. These antigens serve as potential targets for the immune system and are key to developing personalized vaccines. Neoantigen vaccines are designed to identify and target these mutated proteins, stimulating the immune system to recognize and destroy cancer cells or infected cells that harbor these mutations. The beauty of neoantigen-based vaccines lies in their ability to generate highly specific immune responses, as the antigens are unique to the tumor or pathogen, minimizing the risk of off-target effects. This approach has shown promise in cancer immunotherapy, offering potential treatments for cancers that are otherwise difficult to treat. By tailoring vaccines to an individual’s specific neoantigens, researchers can develop personalized therapies that enhance immune surveillance and improve the effectiveness of treatments for both cancer and infectious diseases.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States